CD8A and cancer: Insufficient CD8+ T cell infiltration, low PD-L1 expression in cancer cells, and downregulation of major histocompatibility class I (MHC-I) antigen processing and presentation result in a “cold” (immunological ignorance) TME that typically does not respond to ICI therapy (16, 35, 36).